Vanguard disaggregates holdings; ABT shows 0 shares (ABT)
Rhea-AI Filing Summary
Abbott Laboratories received an amended Schedule 13G/A from The Vanguard Group stating that, following an internal realignment, Vanguard and certain subsidiaries will report beneficial ownership separately. The filing lists Amount beneficially owned: 0 shares and Percent of class: 0% with an effective date shown as 03/13/2026.
Positive
- None.
Negative
- None.
Insights
Vanguard disaggregated holdings; this filing reports no beneficial ownership in Abbott.
The filing states that, after an internal realignment described in the text, certain Vanguard subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538. The entry lists 0 shares and 0% as the reported position.
Dependencies include the internal allocation of holdings across Vanguard entities and the continued reliance on Release No. 34-39538. Subsequent filings from Vanguard may show separate beneficial ownership for related entities; timing and amounts for those separate reports are not included here.